

# ESMO Preceptorship on Supportive and Palliative Care

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**LUGANO SWITZERLAND  
3-4 MAY 2024**

**Co-Chairs**

Karin Jordan, Germany

Christina Ruhlmann, Denmark

# ESMO PRECEPTORSHIP PROGRAMME SUPPORTIVE AND PALLIATIVE CARE

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

Lugano, Switzerland  
3-4 May 2024

**CO-CHAIRS** Karin Jordan, Germany  
Christina Ruhlmann, Denmark

**SPEAKERS** Jann Arends, Germany  
Paolo Bossi, Italy  
Maria Die-Trill, Spain  
Berit Jordan, Germany  
Barry Laird, United Kingdom  
Jayne Wood, United Kingdom

## LEARNING OBJECTIVES

- Understand mechanisms, risk, prevention and treatment of the key symptoms and syndromes: pain, anorexia, cachexia, dyspnea, nausea, vomiting, diarrhoea, constipation, mucositis, neurotoxicity, cardiovascular events, venous thromboembolism, haematological complications and their association with cancer disease and antineoplastic treatment
- Understand integration of screening for and assessment of toxicities to antineoplastic treatment, symptoms and other supportive and palliative care needs, and integration of their management in routine oncology care
- Understand the role of rehabilitation in the continuum of care process
- Understand key steps to prepare patients and family members for end-of-life and care of the dying person
- Understand how to communicate with patients about illness, prognosis, coping, hope and decisions. Reflect on your own role and how to address cultural differences
- Get familiar with the ESMO Clinical Practice Guidelines on supportive and palliative care topics

## ACCREDITATION

The programme of this event has been accredited with **12 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 3 May 2024

<b>09:00-09:10</b> 10'	<b>Opening and welcome</b>	<b>Karin Jordan, DE</b> <b>Christina Ruhlmann, DK</b>
10'	Course Introduction – Preceptorship goals, learning objectives, and the ESMO/ASCO Global Curriculum in Medical Oncology	Karin Jordan, DE
<b>09:10-10:25</b> 75'	<b>SESSION 1</b> <b>Overview of main issues of supportive and palliative care</b>	<b>Chair:</b> <b>Christina Ruhlmann, DK</b>
15'	ESMO Clinical Practice Guidelines on Supportive and Palliative Care: A few words on how to navigate and methods	Karin Jordan, DE
5'	Q&A	
15'	Rehabilitation: An emerging integral part of supportive and palliative care	Jann Arends, DE
5'	Q&A	
20'	Communication with cancer patients: Challenging situations, breaking bad news, family perspectives, desire to hasten death – Part 1	Maria Die-Trill, ES
5'	Q&A	
10'	Participant clinical case discussion (1x10')	Faculty
<b>10:25-10:55</b>	<b>Coffee break</b>	
<b>10:55-12:55</b> 120'	<b>SESSION 2</b> <b>Prevention and treatment of complications, toxicities, and symptoms</b>	<b>Chair:</b> <b>Jayne Wood, UK</b>
20'	Chemotherapy-induced peripheral neuropathy: Mechanism, prevention and treatment	Berit Jordan, DE
5'	Q&A	
20'	Management of cancer related pain	Barry Laird, UK
5'	Q&A	
20'	Complex symptom management in palliative care	Jayne Wood, UK
5'	Q&A	
20'	Communication with cancer patients: Challenging situations, breaking bad news, family perspectives, desire to hasten death – Part 2	Maria Die-Trill, ES
5'	Q&A	
20'	Participants clinical case discussion (2x10')	Faculty
<b>12:55-13:55</b>	<b>Lunch</b>	
<b>13:55-15:10</b> 75'	<b>SESSION 3</b> <b>Vessels, blood and bonemarrow</b>	<b>Chair:</b> <b>Christina Ruhlmann, DK</b>
20'	Extravasation of anticancer agents	Karin Jordan, DE
5'	Q&A	
20'	Cancer associated venous thromboembolism: Mechanism and management	Christina Ruhlmann, DK
5'	Q&A	
10'	Neutropenia – febrile neutropenia, anemia still a problem?	Paolo Bossi, IT
5'	Q&A	
10'	Participant clinical case discussion (1x10')	Faculty
<b>15:10-16:20</b> 70'	<b>SESSION 4</b> <b>Digestive tract symptoms and toxicity</b>	<b>Chair:</b> <b>Karin Jordan, DE</b>
25'	Anticancer therapy-induced mucositis and diarrhoea: Prevention and management strategies	Paolo Bossi, IT
5'	Q&A	
10'	Participant clinical case discussion (1x10')	Faculty
15'	Constipation in advanced cancer	Barry Laird, UK
5'	Q&A	
10'	Participant clinical case discussion (1x10')	Faculty
<b>16:20-16:50</b>	<b>Coffee break</b>	

<b>16:50-18:30</b> 100'	<b>SESSION 5</b> <b>Digestive tract symptoms and toxicity - Continued</b>	<b>Chair:</b> <b>Paolo Bossi, IT</b>
20' 5'	Prevention and management of cancer disease and chemo- and radiotherapy-induced nausea and vomiting, guidelines update and future directions Q&A	Karin Jordan, DE
15' 5'	Clinical cases discussion Q&A	Christina Ruhlmann, DK
20' 5'	Cancer cachexia: Practical assessment, prevention and treatment, including indication for invasive nutrition Q&A	Jann Arends, DE
20' 5'	Fasting, cancer-diets, probiotics and the influence on the Microbiome Q&A	Jann Arends, DE
5'	Closing remarks Day 1	Karin Jordan, DE Christina Ruhlmann, DK
<b>19:30</b>	<b>Dinner</b>	

## Saturday, 4 May 2024

<b>08:30-09:10</b> 40'	<b>SESSION 6</b> <b>Challenging symptom management</b>	<b>Chair:</b> <b>Christina Ruhlmann, DK</b>
15' 5'	Delirium and palliative sedation Q&A	Barry Laird, UK
15' 5'	Rare and life threatening immunotoxicities: How to manage Q&A	Christina Ruhlmann, DK
<b>09:10-10:30</b> 80'	<b>SESSION 7</b> <b>Early palliative care</b>	<b>Chair:</b> <b>Maria Die-Trill, ES</b>
15' 5'	Early integration of palliative care across different care settings and professions Q&A	Jayne Wood, UK
20' 5'	Care at the end of life: Basic knowledge for the oncologist Q&A	Jayne Wood, UK
20' 5'	The challenges of patient reported outcomes Q&A	Karin Jordan, DE
10'	Participant clinical case discussion (1x10')	Faculty
<b>10:30-11:00</b>	<b>Coffee break</b>	
<b>11:00-12:20</b> 80'	<b>SESSION 8</b> <b>Patient care: Burning questions and practical implications</b>	<b>Chair:</b> <b>Karin Jordan, DE</b>
20' 5'	Management of toxicities from immunotherapy – clinical cases Q&A	Christina Ruhlmann, DK
15' 5'	Central neurotoxicity Q&A	Berit Jordan, DE
10' 5'	Polyneuropathy: Practical and focused examination from the neurological perspective Q&A	Berit Jordan, DE
20'	Participants clinical case discussion (2x10')	Faculty
<b>12:20-13:00</b> 40'	<b>SESSION 9</b> <b>Speakers corner Q&amp;A</b>	<b>Chairs:</b> <b>Karin Jordan, DE</b> <b>Christina Ruhlmann, DK</b>
<b>13:00-13:10</b> 10'	<b>Conclusion, evaluation and farewell</b>	<b>Karin Jordan, DE</b> <b>Christina Ruhlmann, DK</b>
<b>13:10-14:10</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for participant clinical case discussion includes a 5' case presentation and a 5' Q&A / discussion